Program Committee

Dana Goldman, PhD
Chair, Professor, USC Schaeffer Center for Health Policy & Economics, Los Angeles, California, USA

Jan Elias Hansen, PhD
Vice President, Evidence for Access Unit, US Medical Affairs at Genentech, South San Francisco, CA, USA

Nicola Bedlington
Special Advisor, European Patients' Forum, Brussels, Belgium

Josh J. Carlson, MPH, PhD
Associate Professor, The Comparative Health Outcomes, Policy, and Economics, (CHOICE) Institute, School of Pharmacy, University of Washington, Seattle, WA, USA

Laura A. Hatfield, PhD
Associate Professor of Health Care Policy (Biostatistics),
Department of Health Care Policy, Harvard Medical School, Boston, MA, USA

Lori McLeod, PhD
Vice President, Patient-Centered Outcomes Assessment, RTI Health Solutions,
Research Triangle Park, NC, USA

James F. Murray, PhD
Research Fellow, Global Patient Outcomes and Real World
Evidence, Eli Lilly and Company, Indianapolis, IN, USA

Issue Panel/Workshop Review Committee

Bertalan Nemeth, MSc
Principal Researcher,
Syreon Research Institute,
Budapest, Hungary

Hemant Phatak, PhD
Head, Data Analytics and Value Assessment, North America Medical
Affairs at EMD Serono, Inc., Rockland, MA, USA

Claire Rothery, PhD
Senior Research Fellow in Health Economics, 
Centre for Health Economics, University of York,
Heslington, York, UK

Maureen Smith, MEd
Board Member, Canadian Organization for Rare Disorders (CORD) and Patient Member, Ontario Committee to Evaluate Drugs and Ontario Health Technology Assessment Committee,
Ontario, ON, Canada